



PerkinElmer Collaborates With Leading Life Science Incubators LabCentral and MBC BioLabs to Help Further Drug Discovery

October 14, 2021

Will provide automated protein characterization, cell imaging and cell counting technologies, along with expertise and training

October 14, 2021

WHAT: [PerkinElmer, Inc.](#), a global leader committed to innovating for a healthier world, today announced it is collaborating with leading life science incubators [LabCentral](#) in Boston, Massachusetts and [MBC BioLabs](#) in San Francisco, California to provide innovative, drug discovery technologies, expertise and training to help pharma and biotech start-ups more quickly and accurately identify and accelerate potential clinical trial candidates.

HOW: The PerkinElmer technologies to be used at both dynamic springboard communities will help optimize scientific workflows. These will include the [LabChip® GXII Touch™](#) system, which allows for protein characterization in as little as 42 seconds and requires minimal sample prep, and the [MuviCyte™ Live Cell Imaging System](#), with three-color fluorescence imaging and multiple movie modes, optimal cell maintenance support and flexible assay performance.

LabCentral and MBC BioLabs will also use the [Victor® NIVO™ plate reader](#), the industry's most compact plate reader supporting all popular detection modes, and the [Envision® Multimode Plate Reader](#), along with reagents from PerkinElmer's extensive portfolio. In addition, at LabCentral, PerkinElmer's Nexcelom® [Celigo® Image Cytometer](#), a multichannel brightfield and fluorescent imaging technology for 2D and 3D cultures, and [Cellaca® MX High-throughput Cell Counter](#), which processes 24 samples with fluorescence in 2.5 minutes or less, will be employed.

These innovative additions join other PerkinElmer technologies already at work at one or both of the communities, including cell line engineering, siRNA, and shRNA solutions and reagents from [Horizon Discovery](#) and [Cellometer® Auto 2000 Cell Viability Counter](#) systems from Nexcelom.

WHY: Commenting on the expanding collaboration with the leading incubators, Alan Fletcher, Ph.D., senior vice president, life science at PerkinElmer, said, "Getting leading edge drug discovery technologies and best practices into the hands of up-and-coming organizations is an exciting way to further new thinking around how to treat and prevent the world's most challenging diseases and viruses. We are thrilled to be involved with both the MBC BioLabs and LabCentral communities as their scientists and business teams work to bubble-up novel technologies and breakthrough drug candidates to improve human health."

Douglas Crawford, Ph.D., co-founder and general manager, MBC BioLabs, added, "We are committed to helping startups quickly generate vital data and thrilled to collaborate with PerkinElmer to bring state-of-the-art equipment to the 100+ companies in our labs. These research tools enable our companies to move swiftly from concept to results."

Johannes Fruehauf, MD, PhD, co-founder, president, LabCentral, also said, "The innovations and expertise PerkinElmer is bringing to LabCentral will further enable our resident companies in the development of their ground-breaking life science technologies and drug discovery work. We are excited to welcome PerkinElmer to our network, expanding on the dynamic cell and gene technologies already in action here from Nexcelom and Horizon Discovery."

MORE: From research to clinical trials and the manufacturing of new drugs and vaccines, PerkinElmer is helping scientists accelerate the discovery-to-commercialization process. To learn more about PerkinElmer's life sciences efforts around the globe, please visit: <https://www.perkinelmer.com/corporate/what-we-do/markets/life-sciences.html>.

About PerkinElmer

PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 15,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately \$3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com.

###

Media Contact

Jennifer McNeil

jennifer.mcneil@perkinelmer.com

1 508.380.2902